Skip to main content
Top
Published in: AIDS Research and Therapy 1/2014

Open Access 01-12-2014 | Research

Race/ethnicity and HAART initiation in a military HIV infected cohort

Authors: Erica N Johnson, Mollie P Roediger, Michael L Landrum, Nancy F Crum-Cianflone, Amy C Weintrob, Anuradha Ganesan, Jason F Okulicz, Grace E Macalino, Brian K Agan, the Infectious Disease Clinical Research Program HIV Working Group

Published in: AIDS Research and Therapy | Issue 1/2014

Login to get access

Abstract

Background

Prior studies have suggested that HAART initiation may vary by race/ethnicity. Utilizing the U.S. military healthcare system, which minimizes confounding from healthcare access, we analyzed whether timing of HAART initiation and the appropriate initiation of primary prophylaxis among those at high risk for pneumocystis pneumonia (PCP) varies by race/ethnicity.

Methods

Participants in the U.S. Military HIV Natural History Study from 1998-2009 who had not initiated HAART before 1998 and who, based on DHHS guidelines, had a definite indication for HAART (CD4 <200, AIDS event or severe symptoms; Group A), an indication to consider HAART (including CD4 <350; Group B) or electively started HAART (CD4 >350; Group C) were analyzed for factors associated with HAART initiation. In a secondary analysis, participants were also evaluated for factors associated with starting primary PCP prophylaxis within four months of a CD4 count <200 cells/mm3. Multiple logistic regression was used to compare those who started vs. delayed therapy; comparisons were expressed as odds ratios (OR).

Results

1262 participants were evaluated in the analysis of HAART initiation (A = 208, B = 637, C = 479 [62 participants were evaluated in both Groups A and B]; 94% male, 46% African American, 40% Caucasian). Race/ethnicity was not associated with HAART initiation in Groups A or B. In Group C, African American race/ethnicity was associated with lower odds of initiating HAART (OR 0.49, p = 0.04). Race and ethnicity were also not associated with the initiation of primary PCP prophylaxis among the 408 participants who were at risk.

Conclusions

No disparities in the initiation of HAART or primary PCP prophylaxis according to race/ethnicity were seen among those with an indication for therapy. Among those electively initiating HAART at the highest CD4 cell counts, African American race/ethnicity was associated with decreased odds of starting. This suggests that free healthcare can potentially overcome some of the observed disparities in HIV care, but that unmeasured factors may contribute to differences in elective care decisions.
Literature
1.
go back to reference Palella FJ, Delaney KM, Moorman AC: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301CrossRefPubMed Palella FJ, Delaney KM, Moorman AC: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301CrossRefPubMed
2.
go back to reference Palella FJ, Deloria-Knoll M, Chmiel JS: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003, 138: 620-626. 10.7326/0003-4819-138-8-200304150-00007CrossRefPubMed Palella FJ, Deloria-Knoll M, Chmiel JS: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003, 138: 620-626. 10.7326/0003-4819-138-8-200304150-00007CrossRefPubMed
3.
go back to reference Gras L, Kesselring AM, Griffith JT: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007, 45: 183-192. 10.1097/QAI.0b013e31804d685bCrossRefPubMed Gras L, Kesselring AM, Griffith JT: CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007, 45: 183-192. 10.1097/QAI.0b013e31804d685bCrossRefPubMed
4.
go back to reference Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44: 441-446. 10.1086/510746CrossRefPubMed Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007, 44: 441-446. 10.1086/510746CrossRefPubMed
5.
go back to reference Emery S, Neuhaus JA, Phillips AN: Major clinical outcomes in antiretroviral therapy in (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008, 197: 1133-1144.CrossRefPubMed Emery S, Neuhaus JA, Phillips AN: Major clinical outcomes in antiretroviral therapy in (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008, 197: 1133-1144.CrossRefPubMed
6.
go back to reference Kitahata MM, Gange SJ, Abraham AG: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009, 360: 1815-1826. 10.1056/NEJMoa0807252PubMedCentralCrossRefPubMed Kitahata MM, Gange SJ, Abraham AG: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009, 360: 1815-1826. 10.1056/NEJMoa0807252PubMedCentralCrossRefPubMed
7.
go back to reference Sterne JA, May M, Costagliola D: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009, 373: 1352-1363.CrossRefPubMed Sterne JA, May M, Costagliola D: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009, 373: 1352-1363.CrossRefPubMed
8.
go back to reference Turner BJ, Cunningham WE, Duan N: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med. 2000, 160: 2614-2622. 10.1001/archinte.160.17.2614CrossRefPubMed Turner BJ, Cunningham WE, Duan N: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med. 2000, 160: 2614-2622. 10.1001/archinte.160.17.2614CrossRefPubMed
9.
go back to reference Shapiro MF, Morton SC, McCaffrey DF: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. J Am Med Assoc. 1999, 281: 2305-2315. 10.1001/jama.281.24.2305.CrossRef Shapiro MF, Morton SC, McCaffrey DF: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. J Am Med Assoc. 1999, 281: 2305-2315. 10.1001/jama.281.24.2305.CrossRef
10.
go back to reference Gebo KA, Fleishman JA, Conviser R: Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005, 38: 96-103. 10.1097/00126334-200501010-00017CrossRefPubMed Gebo KA, Fleishman JA, Conviser R: Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005, 38: 96-103. 10.1097/00126334-200501010-00017CrossRefPubMed
11.
go back to reference Easterbrook PJ, Phillips AN, Hill T: Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008, 9: 47-56. 10.1111/j.1468-1293.2008.00512.xCrossRefPubMed Easterbrook PJ, Phillips AN, Hill T: Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Med. 2008, 9: 47-56. 10.1111/j.1468-1293.2008.00512.xCrossRefPubMed
12.
go back to reference Cargill VA, Stone VE: HIV/AIDS: a minority health issue. Med Clin North Am. 2005, 89: 895-912. 10.1016/j.mcna.2005.03.005CrossRefPubMed Cargill VA, Stone VE: HIV/AIDS: a minority health issue. Med Clin North Am. 2005, 89: 895-912. 10.1016/j.mcna.2005.03.005CrossRefPubMed
13.
go back to reference Beach MC, Keruly J, Moore RD: Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?. J Gen Intern Med. 2006, 21: 661-665. 10.1111/j.1525-1497.2006.00399.xPubMedCentralCrossRefPubMed Beach MC, Keruly J, Moore RD: Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?. J Gen Intern Med. 2006, 21: 661-665. 10.1111/j.1525-1497.2006.00399.xPubMedCentralCrossRefPubMed
14.
go back to reference Anastos K, Schneider MF, Gange SJ: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005, 39: 537-544.PubMed Anastos K, Schneider MF, Gange SJ: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr. 2005, 39: 537-544.PubMed
15.
go back to reference Silverberg MJ, Wegner SA, Milazzo MJ: Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006, 20: 1531-1538. 10.1097/01.aids.0000237369.41617.0fCrossRefPubMed Silverberg MJ, Wegner SA, Milazzo MJ: Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006, 20: 1531-1538. 10.1097/01.aids.0000237369.41617.0fCrossRefPubMed
16.
go back to reference Hartzell JD, Spooner K, Howard R: Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007, 44: 411-416. 10.1097/QAI.0b013e31802f83a6CrossRefPubMed Hartzell JD, Spooner K, Howard R: Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007, 44: 411-416. 10.1097/QAI.0b013e31802f83a6CrossRefPubMed
17.
go back to reference Weintrob AC, Grandits GA, Agan BK: Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009, 52: 574-580. 10.1097/QAI.0b013e3181b98537CrossRefPubMed Weintrob AC, Grandits GA, Agan BK: Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009, 52: 574-580. 10.1097/QAI.0b013e3181b98537CrossRefPubMed
18.
go back to reference Marconi VC, Grandits GA, Weintrob AC: Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military Natural History Study. AIDS Res Ther. 2010, 7: 14- 10.1186/1742-6405-7-14PubMedCentralCrossRefPubMed Marconi VC, Grandits GA, Weintrob AC: Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military Natural History Study. AIDS Res Ther. 2010, 7: 14- 10.1186/1742-6405-7-14PubMedCentralCrossRefPubMed
20.
go back to reference Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992, 41: 1-19. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992, 41: 1-19.
21.
go back to reference Lemly DC, Shepherd BE, Hulgan T: Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009, 199: 991-998. 10.1086/597124CrossRefPubMed Lemly DC, Shepherd BE, Hulgan T: Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009, 199: 991-998. 10.1086/597124CrossRefPubMed
22.
go back to reference Brodine SK, Starkey MJ, Shaffer RA: Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003, 17: 2521-2527. 10.1097/00002030-200311210-00016CrossRefPubMed Brodine SK, Starkey MJ, Shaffer RA: Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS. 2003, 17: 2521-2527. 10.1097/00002030-200311210-00016CrossRefPubMed
23.
go back to reference Palacio H, Kahn JG, Richards TA, Morin SF: Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002, 117: 233-251. 10.1016/S0033-3549(04)50158-9PubMedCentralCrossRefPubMed Palacio H, Kahn JG, Richards TA, Morin SF: Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002, 117: 233-251. 10.1016/S0033-3549(04)50158-9PubMedCentralCrossRefPubMed
24.
go back to reference Cohen MH, Cook JA, Grey D: Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004, 94: 1147-1151. 10.2105/AJPH.94.7.1147PubMedCentralCrossRefPubMed Cohen MH, Cook JA, Grey D: Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004, 94: 1147-1151. 10.2105/AJPH.94.7.1147PubMedCentralCrossRefPubMed
25.
go back to reference McNaghten AD, Hanson DL, Dworkin MS, Jones JL: Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003, 32: 499-505. 10.1097/00126334-200304150-00006CrossRefPubMed McNaghten AD, Hanson DL, Dworkin MS, Jones JL: Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003, 32: 499-505. 10.1097/00126334-200304150-00006CrossRefPubMed
26.
go back to reference Oramasionwu CU, Brown CM, Lawson KA: Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006. South Med J. 2011, 104: 794-800. 10.1097/SMJ.0b013e318236c23aPubMedCentralCrossRefPubMed Oramasionwu CU, Brown CM, Lawson KA: Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006. South Med J. 2011, 104: 794-800. 10.1097/SMJ.0b013e318236c23aPubMedCentralCrossRefPubMed
27.
go back to reference King WD, Wong MD, Shapiro MF: Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors?. J Gen Intern Med. 2004, 19: 1146-1153. 10.1111/j.1525-1497.2004.30443.xPubMedCentralCrossRefPubMed King WD, Wong MD, Shapiro MF: Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors?. J Gen Intern Med. 2004, 19: 1146-1153. 10.1111/j.1525-1497.2004.30443.xPubMedCentralCrossRefPubMed
28.
go back to reference Osborn CY, Paasche-Orlow MK, Davis TC, Wolf MS: Health literacy: an overlooked factor in understanding HIV health disparities. Am J Prev Med. 2007, 33: 374-378. 10.1016/j.amepre.2007.07.022CrossRefPubMed Osborn CY, Paasche-Orlow MK, Davis TC, Wolf MS: Health literacy: an overlooked factor in understanding HIV health disparities. Am J Prev Med. 2007, 33: 374-378. 10.1016/j.amepre.2007.07.022CrossRefPubMed
29.
go back to reference Reynolds NR, Testa MA, Marc LG: Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004, 8: 141-150.CrossRefPubMed Reynolds NR, Testa MA, Marc LG: Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav. 2004, 8: 141-150.CrossRefPubMed
30.
go back to reference Jensen-Fangel S, Pedersen L, Pedersen C: The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002, 35: 1541-1548. 10.1086/344769CrossRefPubMed Jensen-Fangel S, Pedersen L, Pedersen C: The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis. 2002, 35: 1541-1548. 10.1086/344769CrossRefPubMed
31.
go back to reference Losina E, Schackman BR, Sadownik SN: Racial and sex differences in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009, 49: 1570-1578. 10.1086/644772PubMedCentralCrossRefPubMed Losina E, Schackman BR, Sadownik SN: Racial and sex differences in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009, 49: 1570-1578. 10.1086/644772PubMedCentralCrossRefPubMed
32.
go back to reference Murphy K, Hoover DR, Shi Q: Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS. 2013, 27: 2413-2423. 10.1097/01.aids.0000432537.92958.73PubMedCentralCrossRefPubMed Murphy K, Hoover DR, Shi Q: Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS. 2013, 27: 2413-2423. 10.1097/01.aids.0000432537.92958.73PubMedCentralCrossRefPubMed
33.
go back to reference Lazo M, Gange SJ, Wilson TE: Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007, 45: 1377-1385. 10.1086/522762CrossRefPubMed Lazo M, Gange SJ, Wilson TE: Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007, 45: 1377-1385. 10.1086/522762CrossRefPubMed
34.
go back to reference Bogart LM, Kelly JA, Catz SL, Sosman JM: Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000, 23: 396-404. 10.1097/00126334-200004150-00006CrossRefPubMed Bogart LM, Kelly JA, Catz SL, Sosman JM: Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000, 23: 396-404. 10.1097/00126334-200004150-00006CrossRefPubMed
35.
go back to reference Himelhoch S, Brown CH, Walkup J: HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009, 23: 1735-1742. 10.1097/QAD.0b013e32832b428fPubMedCentralCrossRefPubMed Himelhoch S, Brown CH, Walkup J: HIV patients with psychiatric disorders are less likely to discontinue HAART. AIDS. 2009, 23: 1735-1742. 10.1097/QAD.0b013e32832b428fPubMedCentralCrossRefPubMed
36.
go back to reference Maisels L, Steinberg J, Tobias C: An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDs. 2001, 15: 185-191. 10.1089/10872910151133701CrossRefPubMed Maisels L, Steinberg J, Tobias C: An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDs. 2001, 15: 185-191. 10.1089/10872910151133701CrossRefPubMed
37.
go back to reference Fairfield KM, Libman H, Davis RB, Eisenberg DM: Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999, 14: 395-401. 10.1046/j.1525-1497.1999.08198.xPubMedCentralCrossRefPubMed Fairfield KM, Libman H, Davis RB, Eisenberg DM: Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999, 14: 395-401. 10.1046/j.1525-1497.1999.08198.xPubMedCentralCrossRefPubMed
Metadata
Title
Race/ethnicity and HAART initiation in a military HIV infected cohort
Authors
Erica N Johnson
Mollie P Roediger
Michael L Landrum
Nancy F Crum-Cianflone
Amy C Weintrob
Anuradha Ganesan
Jason F Okulicz
Grace E Macalino
Brian K Agan
the Infectious Disease Clinical Research Program HIV Working Group
Publication date
01-12-2014
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2014
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-11-10

Other articles of this Issue 1/2014

AIDS Research and Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.